Zacks Research Predicts Reduced Earnings for Kodiak Sciences

Key Points

• Zacks Research has revised its earnings per share estimate for Kodiak Sciences for Q3 2025 to ($1.06), down from a previous forecast of ($1.03).
• The consensus estimate for Kodiak Sciences' full-year earnings is now projected to be ($3.45) per share, with further reductions expected in subsequent years.
• Kodiak Sciences has received upgraded ratings from multiple analysts, with price targets reaching as high as $17.00, while currently holding a consensus rating of "Hold" and a price target of $13.00.

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Zacks Research cut their Q3 2025 earnings per share estimates for shares of Kodiak Sciences in a report issued on Wednesday, September 24th. Zacks Research analyst Team now forecasts that the company will post earnings of ($1.06) per share for the quarter, down from their previous forecast of ($1.03). The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. Zacks Research also issued estimates for Kodiak Sciences' Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($4.28) EPS, Q1 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($1.07) EPS, Q4 2026 earnings at ($1.17) EPS, FY2026 earnings at ($4.09) EPS, Q1 2027 earnings at ($0.85) EPS, Q2 2027 earnings at ($0.92) EPS and FY2027 earnings at ($3.98) EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.02).

KOD has been the subject of several other reports. Jefferies Financial Group started coverage on Kodiak Sciences in a research report on Monday. They set a "buy" rating and a $15.00 price objective for the company. Barclays upgraded Kodiak Sciences from an "underweight" rating to an "equal weight" rating and boosted their price target for the company from $7.00 to $17.00 in a report on Thursday. HC Wainwright boosted their price target on Kodiak Sciences from $3.00 to $5.00 and gave the company a "neutral" rating in a report on Monday, August 18th. Finally, JPMorgan Chase & Co. upgraded Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 price target for the company in a report on Thursday, August 14th. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Kodiak Sciences presently has a consensus rating of "Hold" and a consensus price target of $13.00.

Kodiak Sciences Price Performance

Shares of Kodiak Sciences stock opened at $15.68 on Friday. Kodiak Sciences has a 1 year low of $1.92 and a 1 year high of $19.39. The company has a market capitalization of $828.22 million, a P/E ratio of -4.13 and a beta of 2.45. The business has a 50 day moving average price of $9.20 and a 200 day moving average price of $5.52.

Institutional Trading of Kodiak Sciences

Institutional investors and hedge funds have recently made changes to their positions in the company. US Bancorp DE increased its holdings in shares of Kodiak Sciences by 131.7% during the 1st quarter. US Bancorp DE now owns 9,282 shares of the company's stock worth $26,000 after buying an additional 5,276 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in Kodiak Sciences during the 1st quarter worth $28,000. Headlands Technologies LLC boosted its position in Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock worth $30,000 after purchasing an additional 5,815 shares during the period. Walleye Capital LLC purchased a new stake in Kodiak Sciences during the 1st quarter worth $49,000. Finally, Vanguard Personalized Indexing Management LLC lifted its position in shares of Kodiak Sciences by 21.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company's stock worth $56,000 after purchasing an additional 2,691 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.